ROTUNNO, GIADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.891
EU - Europa 2.611
AS - Asia 952
SA - Sud America 138
AF - Africa 21
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.880
RU - Federazione Russa 897
PL - Polonia 473
IT - Italia 411
SG - Singapore 285
HK - Hong Kong 266
CN - Cina 231
IE - Irlanda 218
SE - Svezia 170
BR - Brasile 123
DE - Germania 116
FI - Finlandia 80
CH - Svizzera 70
FR - Francia 60
GB - Regno Unito 44
IN - India 42
JO - Giordania 39
NL - Olanda 20
VN - Vietnam 19
AU - Australia 17
ES - Italia 17
ID - Indonesia 15
CI - Costa d'Avorio 12
CA - Canada 10
BE - Belgio 8
AT - Austria 7
TW - Taiwan 7
UZ - Uzbekistan 7
BD - Bangladesh 6
PK - Pakistan 6
UA - Ucraina 6
BG - Bulgaria 5
SA - Arabia Saudita 5
TR - Turchia 5
AR - Argentina 3
IQ - Iraq 3
JP - Giappone 3
KE - Kenya 3
KR - Corea 3
PY - Paraguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
EG - Egitto 2
MY - Malesia 2
PE - Perù 2
PH - Filippine 2
RO - Romania 2
TN - Tunisia 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
IM - Isola di Man 1
KZ - Kazakistan 1
LV - Lettonia 1
MX - Messico 1
NO - Norvegia 1
NP - Nepal 1
UY - Uruguay 1
Totale 7.631
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.069
Warsaw 467
Fairfield 414
Ashburn 257
Hong Kong 227
Woodbridge 225
Chandler 222
Dublin 218
Seattle 201
Singapore 163
Cambridge 158
Houston 154
Wilmington 147
Ann Arbor 112
Florence 96
Altamura 82
Lawrence 80
Beijing 72
Bern 70
Princeton 60
Munich 52
Buffalo 46
Boston 34
Moscow 33
Bremen 30
Shanghai 30
San Diego 29
Turku 28
Los Angeles 26
Mumbai 25
New York 25
Paris 25
Helsinki 24
Hefei 23
Medford 21
Melbourne 17
São Paulo 16
Barcelona 15
Jakarta 15
Kent 15
Boardman 14
Rome 13
Abidjan 12
Dearborn 12
Dong Ket 12
Hillsboro 11
Norwalk 9
Brussels 8
Claymont 8
Milan 8
Fuzhou 7
Hangzhou 7
Pune 7
Tashkent 7
Brooklyn 6
Cagliari 6
Fiesole 6
London 6
Pian di Scò 6
San Jose 6
Düsseldorf 5
Vienna 5
Andover 4
Blagoevgrad 4
Cantagallo 4
Frankfurt am Main 4
Guangzhou 4
Jacksonville 4
Nanjing 4
Phoenix 4
Red Deer 4
Redwood City 4
Romainville 4
Salvador 4
San Francisco 4
Siena 4
The Dalles 4
Yubileyny 4
Altopascio 3
Amsterdam 3
Bengaluru 3
Berlin 3
Brescia 3
Campinas 3
Charlotte 3
Curitiba 3
Faenza 3
Falkenstein 3
Jeddah 3
Jinan 3
Kilburn 3
Nairobi 3
Nanchang 3
Newark 3
Pavia 3
Porto Alegre 3
Rio de Janeiro 3
Rochester 3
Seoul 3
Abu Dhabi 2
Totale 5.333
Salva come PNG Salva come JPEG
Nome #
Study of mutation complexity in Chronic Myeloproliferative Neoplasms: pathogenetic insights and translational relevance 304
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 290
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 236
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 235
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 205
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 192
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 182
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 180
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 167
Mutations and prognosis in primary myelofibrosis. 164
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 161
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 160
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 158
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 156
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 156
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 156
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 154
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 153
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 153
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 147
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 147
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 146
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 145
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 145
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 143
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 143
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 139
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 135
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 129
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 128
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 125
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 120
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 120
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 119
Validation of the Mayo alliance prognostic system for mastocytosis 115
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 115
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 113
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 110
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? 110
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 108
Prognotic Impact of Mutations in Systemic Mastocytosis 108
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 107
CALR mutation burden in essential thrombocythemia and disease outcome 102
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 100
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 100
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 99
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 94
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 91
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 86
Prognostic relevance of mutations in myelofi-brosis 84
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 83
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 79
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 76
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 69
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 63
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients 59
null 47
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting 39
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML 18
Totale 7.768
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021619 42 64 13 120 29 49 31 40 67 76 54 34
2021/2022379 9 8 48 17 20 21 13 40 20 14 74 95
2022/20231.160 87 228 72 79 71 173 140 89 103 13 26 79
2023/2024481 25 40 64 18 51 60 12 102 11 32 34 32
2024/20253.139 84 283 196 502 845 494 72 144 130 101 141 147
2025/2026148 148 0 0 0 0 0 0 0 0 0 0 0
Totale 7.768